Severe Clostridioides difficile Infection in the Intensive Care Unit-Medical and Surgical Management.

Infect Dis Clin North Am

Emory University, Emory University Hospital, American College of Surgeons Board of Governors, SESC DEI Committee, ECCC IDEA Committee, Surgical Section of the NMA and Surgical Leaders Foundation, Emory School of Medicine African American Women's Collaborative.

Published: December 2022

Clostridioides difficile remains a major cause of morbidity and mortality in the intensive care unit, and therefore, C difficile guidelines are frequently being updated. Currently, fidaxomicin is the suggested treatment of initial and recurrent infection. Oral vancomycin is an acceptable alternative, followed by rifaximin and fecal microbiota transplantation. Bezlotoxumab is suggested in recurrent cases within 6 months. If patients fail to improve within 3 to 5 days of therapy, especially in patients who have had nasogastric tubes or emergent surgery, fulminant colitis is possible and surgical consultation should be considered for total colectomy.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.idc.2022.07.006DOI Listing

Publication Analysis

Top Keywords

clostridioides difficile
8
intensive care
8
severe clostridioides
4
difficile infection
4
infection intensive
4
care unit-medical
4
unit-medical surgical
4
surgical management
4
management clostridioides
4
difficile remains
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!